These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31113223)

  • 1. The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review.
    Davis MP; Behm B; Mehta Z; Fernandez C
    Am J Hosp Palliat Care; 2019 Dec; 36(12):1134-1154. PubMed ID: 31113223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-palmitoylethanolamide in the anterior cingulate cortex attenuates inflammatory pain behaviour indirectly via a CB1 receptor-mediated mechanism.
    Okine BN; Madasu MK; McGowan F; Prendergast C; Gaspar JC; Harhen B; Roche M; Finn DP
    Pain; 2016 Dec; 157(12):2687-2696. PubMed ID: 27649266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palmitoylethanolamide attenuates PTZ-induced seizures through CB1 and CB2 receptors.
    Aghaei I; Rostampour M; Shabani M; Naderi N; Motamedi F; Babaei P; Khakpour-Taleghani B
    Epilepsy Res; 2015 Nov; 117():23-8. PubMed ID: 26370914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of palmitoylethanolamide (PEA) in depression: Translational evidence: Special Section on "Translational and Neuroscience Studies in Affective Disorders". Section Editor, Maria Nobile MD, PhD. This Section of JAD focuses on the relevance of translational and neuroscience studies in providing a better understanding of the neural basis of affective disorders. The main aim is to briefly summaries relevant research findings in clinical neuroscience with particular regards to specific innovative topics in mood and anxiety disorders.
    De Gregorio D; Manchia M; Carpiniello B; Valtorta F; Nobile M; Gobbi G; Comai S
    J Affect Disord; 2019 Aug; 255():. PubMed ID: 30391203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palmitoylethanolamide in CNS health and disease.
    Mattace Raso G; Russo R; Calignano A; Meli R
    Pharmacol Res; 2014 Aug; 86():32-41. PubMed ID: 24844438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel composite formulation of palmitoylethanolamide and quercetin decreases inflammation and relieves pain in inflammatory and osteoarthritic pain models.
    Britti D; Crupi R; Impellizzeri D; Gugliandolo E; Fusco R; Schievano C; Morittu VM; Evangelista M; Di Paola R; Cuzzocrea S
    BMC Vet Res; 2017 Aug; 13(1):229. PubMed ID: 28768536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palmitoylethanolamide is a new possible pharmacological treatment for the inflammation associated with trauma.
    Esposito E; Cuzzocrea S
    Mini Rev Med Chem; 2013 Feb; 13(2):237-55. PubMed ID: 22697514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARĪ±) and its lipid ligands.
    Fidaleo M; Fanelli F; Ceru MP; Moreno S
    Curr Med Chem; 2014; 21(24):2803-21. PubMed ID: 24606520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution.
    Skaper SD; Facci L; Barbierato M; Zusso M; Bruschetta G; Impellizzeri D; Cuzzocrea S; Giusti P
    Mol Neurobiol; 2015 Oct; 52(2):1034-42. PubMed ID: 26055231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEA prevented early BBB disruption after cerebral ischaemic/reperfusion (I/R) injury through regulation of ROCK/MLC signaling.
    Kong D; Xie B; Li Y; Xu Y
    Biochem Biophys Res Commun; 2021 Aug; 566():164-169. PubMed ID: 34126347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review.
    Passavanti MB; Alfieri A; Pace MC; Pota V; Sansone P; Piccinno G; Barbarisi M; Aurilio C; Fiore M
    Syst Rev; 2019 Jan; 8(1):9. PubMed ID: 30621775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of a fixed combination of palmitoylethanolamide and acetyl-l-carnitine (PEA+ALC FC) in the treatment of neuropathies secondary to rheumatic diseases.
    Parisi S; Ditto MC; Borrelli R; Fusaro E
    Minerva Med; 2021 Aug; 112(4):492-499. PubMed ID: 34056884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palmitoylethanolamide reduces inflammation and itch in a mouse model of contact allergic dermatitis.
    Vaia M; Petrosino S; De Filippis D; Negro L; Guarino A; Carnuccio R; Di Marzo V; Iuvone T
    Eur J Pharmacol; 2016 Nov; 791():669-674. PubMed ID: 27720681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Palmitoylethanolamide: from endogenous cannabimimetic substance to innovative medicine for the treatment of cannabis dependence.
    Coppola M; Mondola R
    Med Hypotheses; 2013 Oct; 81(4):619-22. PubMed ID: 23896215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of palmitoylethanolamide in a rat model of cystitis.
    Pessina F; Capasso R; Borrelli F; Aveta T; Buono L; Valacchi G; Fiorenzani P; Di Marzo V; Orlando P; Izzo AA
    J Urol; 2015 Apr; 193(4):1401-8. PubMed ID: 25463999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind randomized placebo controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis.
    Steels E; Venkatesh R; Steels E; Vitetta G; Vitetta L
    Inflammopharmacology; 2019 Jun; 27(3):475-485. PubMed ID: 30927159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems.
    De Petrocellis L; Bisogno T; Ligresti A; Bifulco M; Melck D; Di Marzo V
    Fundam Clin Pharmacol; 2002 Aug; 16(4):297-302. PubMed ID: 12570018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders.
    Assogna M; Di Lorenzo F; Martorana A; Koch G
    Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of palmitoylethanolamide and silymarin combination treatment in an animal model of kidney ischemia and reperfusion.
    Impellizzeri D; Bruschetta G; Ahmad A; Crupi R; Siracusa R; Di Paola R; Paterniti I; Prosdocimi M; Esposito E; Cuzzocrea S
    Eur J Pharmacol; 2015 Sep; 762():136-49. PubMed ID: 25981305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans.
    Landolfo E; Cutuli D; Petrosini L; Caltagirone C
    Biomolecules; 2022 May; 12(5):. PubMed ID: 35625595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.